Comparative Pharmacology
Head-to-head clinical analysis: BETA HC versus CORTALONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETA HC versus CORTALONE.
BETA-HC vs CORTALONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BETA-HC (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as prostaglandins and leukotrienes. It also inhibits phospholipase A2 and reduces cytokine production.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response, and regulate metabolism.
1-2 tablets (200-400 mg) orally every 6-8 hours as needed for pain; not to exceed 6 tablets (1200 mg) per day.
10-40 mg orally once daily in the morning; for acute exacerbations, up to 60 mg/day divided into 2-4 doses.
None Documented
None Documented
1.5 hours (beta phase); clinical context: anti-inflammatory effects persist longer than serum levels due to receptor binding and gene transcription
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Renal (approximately 75% as metabolites, <5% unchanged); fecal (approximately 15%)
Primarily renal (60-70% as unchanged drug), with 10-20% biliary/fecal.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid